Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 20.05.2024 1 Am J Pathol 1 Am J Surg Pathol 3 Ann Oncol 1 Ann Surg Oncol 2 BMC Cancer 3 Br J Cancer 2 Breast Cancer 4 Breast Cancer Res 16 Breast Cancer Res Treat 3 Cancer 1 Cancer Lett 1 Cancer Res 5 Clin Breast Cancer 2 Clin Cancer Res 1 Eur J Surg Oncol 1 Eur Radiol 1 Genes Chromosomes Cancer 1 Histopathology 3 Int J Cancer 2 Int J Radiat Oncol Biol Phys 2 J Clin Invest 1 J Clin Oncol 1 Mod Pathol 1 NPJ Breast Cancer 1 Oncogene 1 Oncol Rep 1 PLoS Med 10 PLoS One 1 Radiol Artif Intell 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. JANA S, Li W, Lei PJ, Wang Z, et al
   Isolation and Characterization of a Novel Mammary Adenocarcinoma, MCa-P1362, with Hormone Receptor Expression, Human Epidermal Growth Factor Receptor 2 Positivity, and Enrichment in Cancer and Mesenchymal Stem Cells.
   Am J Pathol. 2024;194:1137-1153.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

2. MARQUES-PIUBELLI ML, Lyapichev KA, Fnu A, Adrada B, et al
   The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance.
   Am J Surg Pathol. 2024;48:e43-e64.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. GOETZ MP, Toi M, Huober J, Sohn J, et al
   Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
   Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.
   PubMed         Abstract available
   
   
4. HAMILTON E, Oliveira M, Turner N, Garcia-Corbacho J, et al
   A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
   Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.
   PubMed         Abstract available
   
   
5. DENT R, Andre F, Goncalves A, Martin M, et al
   IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
   Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. PARVEZ E, Bogach J, Kirkwood D, Pond G, et al
   ASO Visual Abstract: Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis.
   Ann Surg Oncol. 2024 May 11. doi: 10.1245/s10434-024-15376.
   PubMed        
   
   

   
   BMC Cancer

7. BOUTRUS RR, Abdelazim YA, Mohammed T, Bayomy M, et al
   The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
   BMC Cancer. 2024;24:599.
   PubMed         Abstract available
   
   
8. HAUNER D, Mang A, Donik L, Schederecker F, et al
   Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
   BMC Cancer. 2024;24:591.
   PubMed         Abstract available
   
   

   
   Br J Cancer

9. TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al
   Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
   Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697.
   PubMed         Abstract available
   
   
10. HAM B, Kim SY, Kim YA, Han D, et al
    Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707.
    PubMed         Abstract available
    
    
11. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    PubMed         Abstract available
    
    

    
    Breast Cancer

12. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589.
    PubMed        
    
    
13. DURAN S, Varol U, Tekir O, Soyturk AH, et al
    Resilience's impact on quality of life and post-traumatic growth in breast cancer patients during treatment.
    Breast Cancer. 2024 May 17. doi: 10.1007/s12282-024-01594.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

14. RAJ-KUMAR PK, Lin X, Liu T, Sturtz LA, et al
    Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
    Breast Cancer Res. 2024;26:76.
    PubMed         Abstract available
    
    
15. ZHANG X, Teng X, Zhang J, Lai Q, et al
    Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
    Breast Cancer Res. 2024;26:77.
    PubMed         Abstract available
    
    
16. MARIAPUN S, Ho WK, Eriksson M, Mohd Taib NA, et al
    Association of area- and volumetric-mammographic density and breast cancer risk in women of Asian descent: a case control study.
    Breast Cancer Res. 2024;26:79.
    PubMed         Abstract available
    
    
17. NELSON A, McMullen N, Gebremeskel S, De Antueno R, et al
    Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Breast Cancer Res. 2024;26:78.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

18. WIMMER K, Hlauschek D, Balic M, Pfeiler G, et al
    Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
    Breast Cancer Res Treat. 2024;205:227-239.
    PubMed         Abstract available
    
    
19. MOKBEL K, Alamoodi M
    Reassessing treatment strategies for DCIS: analysis of survival and recurrence patterns.
    Breast Cancer Res Treat. 2024;205:423-424.
    PubMed        
    
    
20. SHIBAHARA Y, Delabie JMA, Kulkarni S, Grant A, et al
    Primary MALT lymphoma of the breast: pathological and radiological characteristics.
    Breast Cancer Res Treat. 2024;205:387-394.
    PubMed         Abstract available
    
    
21. HARVIE M, Livingstone K, McMulllan D, Pegington M, et al
    BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trial.
    Breast Cancer Res Treat. 2024 May 17. doi: 10.1007/s10549-024-07356.
    PubMed         Abstract available
    
    
22. WOO JW, Han EK, Suh KJ, Kim SH, et al
    Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 May 16. doi: 10.1007/s10549-024-07359.
    PubMed         Abstract available
    
    
23. SHI X, Sheng Y, Fei H, Wei B, et al
    Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
    Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07355.
    PubMed         Abstract available
    
    
24. FREEMAN JQ, Sheade JB, Zhao F, Olopade OI, et al
    Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
    Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07363.
    PubMed         Abstract available
    
    
25. GIRO C, Yamada AMTD, Cruz FJSM, do R Barros LA, et al
    Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
    Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07366.
    PubMed         Abstract available
    
    
26. CORIANO M, Tommasi C, Dinh ATL, Needham J, et al
    The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
    Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07336.
    PubMed         Abstract available
    
    
27. YAMADA M, Jinno H, Naruse S, Isono Y, et al
    Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
    Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07370.
    PubMed         Abstract available
    
    
28. ROSENBERG SM, Zeng C, An A, Ssebyala SN, et al
    Characterizing "collateral damage" in men and women with metastatic breast cancer (mBC) from diverse racial and ethnic backgrounds in New York City.
    Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07347.
    PubMed         Abstract available
    
    
29. BOYLE L, Lawrenson R, Nosa V, Campbell I, et al
    Ethnic inequities in use of breast conserving surgery and radiation therapy in Aotearoa/New Zealand: which factors contribute?
    Breast Cancer Res Treat. 2024;205:641-653.
    PubMed         Abstract available
    
    
30. PERERA D, Pirikahu S, Walter J, Cadby G, et al
    The distribution of breast density in women aged 18 years and older.
    Breast Cancer Res Treat. 2024;205:521-531.
    PubMed         Abstract available
    
    
31. LEO CSY, Cheng LJ, Lam XR, He H, et al
    Global prevalence and factors associated with preoperative depression in women undergoing breast surgery: a meta-analysis and meta-regression.
    Breast Cancer Res Treat. 2024;205:425-438.
    PubMed         Abstract available
    
    
32. FRANKLIN J, Hayes J, Knippa E, Dogan B, et al
    False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis.
    Breast Cancer Res Treat. 2024;205:507-520.
    PubMed         Abstract available
    
    
33. GINZAC A, Molnar I, Durando X, Motte Rouge T, et al
    Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
    Breast Cancer Res Treat. 2024;205:267-279.
    PubMed         Abstract available
    
    

    
    Cancer

34. CHLEBOWSKI RT, Aragaki AK, Pan K, Simon MS, et al
    Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
    Cancer. 2024 May 13. doi: 10.1002/cncr.35318.
    PubMed         Abstract available
    
    
35. SCHETTINI F, Blondeaux E, Molinelli C, Bas R, et al
    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35323.
    PubMed         Abstract available
    
    
36. BELAU MH, Jung L, Maurer T, Obi N, et al
    Social relationships and their impact on health-related quality of life in a long-term breast cancer survivor cohort.
    Cancer. 2024 May 17. doi: 10.1002/cncr.35364.
    PubMed         Abstract available
    
    

    
    Cancer Lett

37. RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al
    Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
    Cancer Lett. 2024;591:216879.
    PubMed         Abstract available
    
    

    
    Cancer Res

38. HUANG MY, Hu SY, Dong J, Deng L, et al
    The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
    Cancer Res. 2024 May 15. doi: 10.1158/0008-5472.CAN-23-2781.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

39. WANG L, Liu L, Zhang Z, Li F, et al
    Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
    Clin Breast Cancer. 2024 Apr 23:S1526-8209(24)00110.
    PubMed         Abstract available
    
    
40. HUANG J, Sun S, Tan Q, Zheng F, et al
    Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.
    Clin Breast Cancer. 2024 Apr 6:S1526-8209(24)00101.
    PubMed         Abstract available
    
    
41. GONCALVES ACN, Amorim RB, Domingues BS, Sousa JVA, et al
    Female Sexual Function Index Adaptation for Breast Cancer Patients (FSFI-BC): Brazilian Portuguese Translation and Cultural Adaptation.
    Clin Breast Cancer. 2024 Apr 8:S1526-8209(24)00105.
    PubMed         Abstract available
    
    
42. PEDERSINI R, Buffoni M, Petrelli F, Ghidini A, et al
    Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.
    Clin Breast Cancer. 2024 Apr 8:S1526-8209(24)00103.
    PubMed         Abstract available
    
    
43. GUAN D, Shi Q, Zheng Y, Zheng C, et al
    Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.
    Clin Breast Cancer. 2024 Apr 14:S1526-8209(24)00106.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

44. WANDER SA, Bardia A
    Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
    Clin Cancer Res. 2024;30:2008-2010.
    PubMed         Abstract available
    
    
45. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

46. SAQIB HWU, Arshad HUA
    "Navigating breast cancer treatment: The role of early genetic testing".
    Eur J Surg Oncol. 2024;50:108392.
    PubMed        
    
    

    
    Eur Radiol

47. ALVAREZ-BENITO M
    Imaging evaluation of neoadjuvant breast cancer treatment: where do we stand?
    Eur Radiol. 2024 May 16. doi: 10.1007/s00330-024-10799.
    PubMed        
    
    

    
    Genes Chromosomes Cancer

48. WU S, Yao X, Sun W, Jiang K, et al
    Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.
    Genes Chromosomes Cancer. 2024;63:e23243.
    PubMed         Abstract available
    
    

    
    Histopathology

49. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed         Abstract available
    
    

    
    Int J Cancer

50. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed         Abstract available
    
    
51. GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al
    Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Int J Cancer. 2024;155:339-351.
    PubMed         Abstract available
    
    
52. DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al
    Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

53. LO AC, Ronckers C, Aznar MC, Avanzo M, et al
    Breast Hypoplasia and Decreased Lactation From Radiation Therapy in Survivors of Pediatric Malignancy: A PENTEC Comprehensive Review.
    Int J Radiat Oncol Biol Phys. 2024;119:549-559.
    PubMed         Abstract available
    
    
54. HAHN EA, Pugh SL, Lu HL, Vela AM, et al
    Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial.
    Int J Radiat Oncol Biol Phys. 2024 May 13:S0360-3016(24)00436.
    PubMed         Abstract available
    
    

    
    J Clin Invest

55. MARCHESE E, Demehri S
    Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    J Clin Invest. 2024;134:e180914.
    PubMed         Abstract available
    
    
56. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    J Clin Invest. 2024;134:e176390.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

57. SANTHOSH A, Sharma A, Bakhshi S, Kumar A, et al
    Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1821-1829.
    PubMed         Abstract available
    
    

    
    Mod Pathol

58. DJERROUDI L, El Sabeh-Ayoun A, Benoist C, Pierron G, et al
    Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Mod Pathol. 2024;37:100463.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

59. ALBA-BERNAL A, Godoy-Ortiz A, Dominguez-Recio ME, Lopez-Lopez E, et al
    Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients.
    NPJ Breast Cancer. 2024;10:36.
    PubMed         Abstract available
    
    

    
    Oncogene

60. DORE S, Ali M, Sorin M, McDowell SAC, et al
    Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Oncogene. 2024 May 14. doi: 10.1038/s41388-024-03051.
    PubMed         Abstract available
    
    

    
    Oncol Rep

61. YAO J, Xu T, Tian T, Fu X, et al
    [Retracted] Tripartite motif 16 suppresses breast cancer stem cell properties through regulation of Gli?1 degradation via the ubiquitin?proteasome pathway.
    Oncol Rep. 2024;52:89.
    PubMed         Abstract available
    
    

    
    PLoS Med

62. MOORE-PALHARES D, Dasgupta A, Saifuddin M, Anzola Pena ML, et al
    Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial.
    PLoS Med. 2024;21:e1004408.
    PubMed         Abstract available
    
    

    
    PLoS One

63. SUN G, Cai L, Yan X, Nie W, et al
    A prediction model based on digital breast pathology image information.
    PLoS One. 2024;19:e0294923.
    PubMed         Abstract available
    
    
64. PELICANO AC, Goncalves MCT, Castela T, Orvalho ML, et al
    Repository of MRI-derived models of the breast with single and multiple benign and malignant tumors for microwave imaging research.
    PLoS One. 2024;19:e0302974.
    PubMed         Abstract available
    
    
65. YANG Z, Wang Y, Huang S, Geng Y, et al
    Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer.
    PLoS One. 2024;19:e0303650.
    PubMed         Abstract available
    
    
66. PINTO-CARBO M, Vanaclocha-Espi M, Ibanez J, Martin-Pozuelo J, et al
    Interaction of sedentary behaviour and educational level in breast cancer risk.
    PLoS One. 2024;19:e0300349.
    PubMed         Abstract available
    
    
67. SAITO N, Matsuo T, Tsuda H, Yokota H, et al
    Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
    PLoS One. 2024;19:e0303614.
    PubMed         Abstract available
    
    
68. XIAO J, Tan L, Pei Y, Yang R, et al
    Association between red cell distribution width and all-cause mortality in patients with breast cancer: A retrospective analysis using MIMIC-IV 2.0.
    PLoS One. 2024;19:e0302414.
    PubMed         Abstract available
    
    
69. MUNTER-YOUNG R, Fuentes-Alburo A, DiGregorio N, Neeser K, et al
    Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
    PLoS One. 2024;19:e0302486.
    PubMed         Abstract available
    
    
70. XU Y, Yu J, Shen R, Shan X, et al
    Comparison efficacy and safety of acupuncture and moxibustion therapies in breast cancer-related lymphedema: A systematic review and network meta-analysis.
    PLoS One. 2024;19:e0303513.
    PubMed         Abstract available
    
    
71. LUU TNN, Dinh DX, Tran TX, Tran TB, et al
    Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study.
    PLoS One. 2024;19:e0303011.
    PubMed         Abstract available
    
    
72. KIM SM, Park N, Park HB, Lee J, et al
    Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
    PLoS One. 2024;19:e0303433.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

73. BAE MS
    AI Improves Cancer Detection and Reading Time of Digital Breast Tomosynthesis.
    Radiol Artif Intell. 2024;6:e240219.
    PubMed        
    
    

    
    Radiother Oncol

74. CHRIST SM, Alongi F, Ricardi U, Scorsetti M, et al
    Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E(2)-RADIatE OligoCare study.
    Radiother Oncol. 2024;195:110235.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.